Cardiovascular Systems Inc

Cardiovascular Systems — Q2 FY2022 Earnings Presentation

14 slides from Cardiovascular Systems's earnings presentation, Feb 3, 2022

  1. Slide 1: Q2 FY22 Earnings Supplement

    ©2022 Cardiovascular Systems, Inc. All Rights Reserved. Q2 FY22 Earnings Supplement February 3, 2022

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Q2 FY22 Worldwide Revenues of $59.1 Million

    1.3% increase Q/Q and 7.8% decrease Y/Y Q2 FY22 Worldwide Revenues of $59.1 Million Q2 FY22 Revenue Breakdown Worldwide Peripheral $38.9 -0.3% Q/Q -11.5% Y/Y Worldwide Coronary $20.2 +4.5% Q/Q +0.1% Y/Y Worldwide Peripheral Worldwide Coronary ($ in millions, Q/Q and Y/Y represent Quarter-over-Quarte

  4. Slide 4: Q2 FY22: U.S. Peripheral

    Q2 FY22: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, ViperCath and WIRION Recovery from De

  5. Slide 5: Q2 FY22: U.S. Coronary

    Q2 FY22: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue. 2 Includes coronary orbital atherectomy devices, Coronary ViperWire, ViperSlide and other 3 Includes Sapphire angioplasty balloons and Teleport microcatheters Modest Q/Q growth as

  6. Slide 6: Q2 FY22: International

    Q2 FY22: International Double-digit Q/Q growth driven by Japan and EU coronary 6 Revenue increased 10.1% Q/Q and 62.0% Y/Y • International revenue increased $3.7 million driven by: • Strong growth in Japan despite COVID impacting PCI volumes • EU launch plan remains on track with physicians trained

  7. Slide 7: Q2 FY22 vs. Q1 FY22 and Q2 FY21

    Q2 FY22 vs. Q1 FY22 and Q2 FY21 Dollars in thousands 7 Q2 FY22 Quarter/Quarter Change Year/Year Change Worldwide Revenue $59,135 1.3% -7.8% Worldwide Peripheral Revenue $38,903 -0.3% -11.5% Worldwide Coronary Revenue $20,232 4.5% 0.1% U.S. Revenue $55,471 0.8% -10.4% U.S. Peripheral Revenue $38,813

  8. Slide 8: Q2 FY22: Select Financial Information

    Q2 FY22: Select Financial Information Dollars in thousands, except earnings per share and shares outstanding 8 Q2 FY22 Q1 FY22 Q/Q Change Fav (Unfav) Q2 FY21 Y/Y Change Fav (Unfav) Net revenues $59,135 $58,370 $765 $64,169 ($5,034) Cost of goods sold 18,073* 14,308 (3,765)* 13,920 (4,153) Gross Marg

  9. Slide 9: FY22: Annual Guidance

    FY22: Annual Guidance 9 For the fiscal year ending June 30, 2022, CSI anticipates: Revenue of $235 million to $245 million; Gross profit as a percentage of revenues of approximately 73%; Net loss in a range of 15% to 18% of revenues; and Adjusted EBITDA loss of 4% to 7% of revenues.

  10. Slide 10: Recent Developments January 1, 2022 to date

    Recent Developments January 1, 2022 to date 10

  11. Slide 11: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 11 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense

  12. Slide 12: Non-GAAP Financial Measures

    12 Non-GAAP Financial Measures CSI uses gross margin, excluding WIRION charge, on slide 8. CSI excludes certain one-time charges and costs from this item primarily because such expenses are not ongoing and recurring expenses. CSI’s management believes that excluding these charges is useful to invest

  13. Slide 13: Investor Contact

    Investor Contact: Jack Nielsen 651-202-4919 [email protected] CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire®, WIRION® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc. © 2022 Cardiovascular Systems, Inc. OrbusNeich®, Teleport® and Sapphire® are trademarks of Or

  14. Slide 14: Cardiovascular Systems, Inc.

    CARDIOVASCULAR SYSTEMS, INC. cS. www.csi360.com

Cardiovascular Systems — Q2 FY2022 Earnings Presentation on 6ix